TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Post-operative Regional Analgesia Rather Than Systemic Analgesia to Decrease the Incidence of Post-operative Delirium After Acute Hip Fracture Surgery? A Prospective Randomized-controlled Double-blinded Pilot Study.
Brief Summary: Post operative delirium is common after hip fracture surgery and is associated with increased length of hospital stay, delayed recovery and increased mortality. Postoperative delirium can also decrease a patient's quality of life and increase treatment costs. Anesthesia and pain relief (analgesia) treatments may also influence the incidence of delirium, but more research is needed into which techniques are effective in improving patient outcomes, care and decreasing costs. This pilot study compares the addition of regional analgesia as part of general anesthesia to determine the incidence of delirium following hip surgery. This is a collaborative study involving anesthesia, orthopedic surgery and geriatrics in the improvement of patient care.


Options:
A: Arm Label: morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: morphine | Arm Label: levobupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: levobupivacaine | Intervention Type: DRUG; Name: morphine; Assigned to Arm(s): morphine | Intervention Type: DRUG; Name: levobupivacaine; Assigned to Arm(s): levobupivacaine
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Fascia iliaca block; Type: EXPERIMENTAL; Interventions: Procedure: Fascia iliaca block arm | Intervention Type: PROCEDURE; Name: Fascia iliaca block arm; Assigned to Arm(s): Fascia iliaca block
C: Arm Label: General Anesthesia with nerve block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Femoral Nerve Block | Arm Label: General Anesthesia no nerve block; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Femoral Nerve Block; Assigned to Arm(s): General Anesthesia with nerve block
D: Arm Label: regional anesthesia; Type: N/A; Interventions: N/A | Arm Label: systemic analgesia; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate the effect of preoperative remote ischaemic preconditioning (RIPC) on organ damage and the functional characteristics of arteries in patients undergoing vascular surgery. In addition, we investigate the connection between RIPC and changes in the functional characteristics of arteries and low molecular weight metabolites.


Options:
A: Arm Label: RIPC intervention; Type: EXPERIMENTAL; Interventions: Other: remote ischemic preconditioning | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: remote ischemic preconditioning; Assigned to Arm(s): RIPC intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Remote ischaemic preconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischaemic preconditioning | Arm Label: Control to RIPC; Type: SHAM_COMPARATOR; Interventions: Procedure: Control to RIPC | Intervention Type: PROCEDURE; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Remote ischaemic preconditioning | Intervention Type: PROCEDURE; Name: Control to RIPC; Assigned to Arm(s): Control to RIPC
C: Arm Label: Remote ischaemic preconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischaemic preconditioning | Arm Label: Control to remote preconditioning group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Remote ischaemic preconditioning
D: Arm Label: Sham; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control | Arm Label: RIPC; Type: EXPERIMENTAL; Interventions: Procedure: Preconditioning | Intervention Type: PROCEDURE; Name: Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Sham

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy
Brief Summary: Prospective, non-randomized multicenter study on the safety and efficacy of combination therapy with bendamustine and rituximab for chronic cold agglutinin disease.


Options:
A: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
B: Arm Label: Treatment arm; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Rituximab | Intervention Type: DRUG; Name: Bendamustine, Rituximab; Assigned to Arm(s): Treatment arm
C: Arm Label: M281 administered every 4 weeks (double-blind period); Type: EXPERIMENTAL; Interventions: Drug: M281, Drug: Placebo | Arm Label: M281 administered every 2 weeks (double-blind period); Type: EXPERIMENTAL; Interventions: Drug: M281 | Arm Label: Placebo administered every 2 weeks (double-blind period); Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: M281 administered every 4 weeks (open-label extension period); Type: EXPERIMENTAL; Interventions: Drug: M281 | Arm Label: M281 administered every 2 weeks (open-label extension period); Type: EXPERIMENTAL; Interventions: Drug: M281 | Intervention Type: DRUG; Name: M281; Assigned to Arm(s): M281 administered every 2 weeks (double-blind period), M281 administered every 2 weeks (open-label extension period), M281 administered every 4 weeks (double-blind period), M281 administered every 4 weeks (open-label extension period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): M281 administered every 4 weeks (double-blind period), Placebo administered every 2 weeks (double-blind period)
D: Intervention Type: DRUG; Name: prednisone, low dose rituximab; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Secukinumab on Aortic Vascular Inflammation and Cardiometabolic Biomarkers After 12 Weeks of Treatment, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Brief Summary: This study evaluated the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.


Options:
A: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Non-systemic treatment.; Type: ACTIVE_COMPARATOR; Interventions: Device: UVB Phototherapy, Other: Topical treatment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: DEVICE; Name: UVB Phototherapy; Assigned to Arm(s): Non-systemic treatment. | Intervention Type: OTHER; Name: Topical treatment; Assigned to Arm(s): Non-systemic treatment.
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
C: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300 mg | Arm Label: Placebo then Secukinumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: DRUG; Name: Secukinumab 300 mg; Assigned to Arm(s): Secukinumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo then Secukinumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial Comparing Vaginal Laser Therapy to Vaginal Estrogen Therapy in Women With Genitourinary Syndrome of Menopause
Brief Summary: This is a multi-centered, randomized prospective single blinded clinical trial comparing CO2 fractionated vaginal laser therapy and vaginal estrogen cream therapy in the treatment of vulvovaginal atrophy/GSM.


Options:
A: Arm Label: CO2 fractionated vaginal laser; Type: EXPERIMENTAL; Interventions: Device: CO2 fractionated vaginal laser | Arm Label: Estrogens, Conjugated (USP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Estrogens, Conjugated (USP) | Intervention Type: DEVICE; Name: CO2 fractionated vaginal laser; Assigned to Arm(s): CO2 fractionated vaginal laser | Intervention Type: DRUG; Name: Estrogens, Conjugated (USP); Assigned to Arm(s): Estrogens, Conjugated (USP)
B: Arm Label: PFMT plus routine pessary management; Type: ACTIVE_COMPARATOR; Interventions: Other: PFMT | Arm Label: Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Other: PFMT | Intervention Type: OTHER; Name: PFMT; Assigned to Arm(s): Lifestyle, PFMT plus routine pessary management
C: Arm Label: Premarin cream 0.5gm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vaginal conjugated estrogen cream 0.5gm | Arm Label: Premarin cream 1.0gm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vaginal conjugated estrogen cream 1.0gm | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Vaginal conjugated estrogen cream 0.5gm; Assigned to Arm(s): Premarin cream 0.5gm | Intervention Type: DRUG; Name: Vaginal conjugated estrogen cream 1.0gm; Assigned to Arm(s): Premarin cream 1.0gm
D: Arm Label: Premarin; Type: EXPERIMENTAL; Interventions: Drug: Premarin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Premarin; Assigned to Arm(s): Premarin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial Comparing Vaginal Laser Therapy to Vaginal Estrogen Therapy in Women With Genitourinary Syndrome of Menopause
Brief Summary: This is a multi-centered, randomized prospective single blinded clinical trial comparing CO2 fractionated vaginal laser therapy and vaginal estrogen cream therapy in the treatment of vulvovaginal atrophy/GSM.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: 17-b-estradiol, Drug: 17-b-estradiol + medroxyprogeterone acetate, Drug: 17-b-estradiol hemihydrate, Drug: placebo pill + gel | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 17-b-estradiol, Drug: 17-b-estradiol + medroxyprogeterone acetate, Drug: 17-b-estradiol hemihydrate, Drug: placebo pill + gel | Intervention Type: DRUG; Name: 17-b-estradiol; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 17-b-estradiol + medroxyprogeterone acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 17-b-estradiol hemihydrate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: placebo pill + gel; Assigned to Arm(s): 1, 2
B: Intervention Type: DRUG; Name: estradiol, 10 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estradiol, 25 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conjugated equine estrogens 0.45 mg/day, Drug: Transdermal estradiol, 50 mcg/day, Drug: Micronized progesterone, 200 mg/day x 12 d/month, Drug: CEE, progesterone, transdermal patch or the placebo | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: CEE , progesterone, estradiol patch or placebo for each, Drug: CEE, progesterone, transdermal patch or the placebo | Intervention Type: DRUG; Name: Conjugated equine estrogens 0.45 mg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Transdermal estradiol, 50 mcg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Micronized progesterone, 200 mg/day x 12 d/month; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: CEE , progesterone, estradiol patch or placebo for each; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: CEE, progesterone, transdermal patch or the placebo; Assigned to Arm(s): Arm 1, Arm 2
D: Arm Label: CO2 fractionated vaginal laser; Type: EXPERIMENTAL; Interventions: Device: CO2 fractionated vaginal laser | Arm Label: Estrogens, Conjugated (USP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Estrogens, Conjugated (USP) | Intervention Type: DEVICE; Name: CO2 fractionated vaginal laser; Assigned to Arm(s): CO2 fractionated vaginal laser | Intervention Type: DRUG; Name: Estrogens, Conjugated (USP); Assigned to Arm(s): Estrogens, Conjugated (USP)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating the Accessibility and Utility of HIV-related Point of Care Diagnostic for Maternal Health in Rural South Africa
Brief Summary: Diagnostic point-of-care (POC) tests are being rapidly developed and implemented in resource-limited settings. There has been a rapid rise of HIV and TB POC tests in South Africa during the last 10-15 years. The investigators sought to determine the existing availability, current usage and future need of POC tests among rural primary healthcare (PHC) clinics in South Africa's KwaZulu-Natal Province.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Device: Alere q | Intervention Type: DEVICE; Name: Alere q; Assigned to Arm(s): Intervention
B: Arm Label: Alere q HIV-1/2 Detect for point of care infant testing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Alere q HIV-1/2 Detect for point of care infant testing, Behavioral: HIV DNA PCR testing (Standard of Care) | Arm Label: GeneXpert HIV-1 Qual for point of care infant testing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: GeneXpert HIV-1 Qual for point of care infant testing, Behavioral: HIV DNA PCR testing (Standard of Care) | Intervention Type: BEHAVIORAL; Name: Alere q HIV-1/2 Detect for point of care infant testing; Assigned to Arm(s): Alere q HIV-1/2 Detect for point of care infant testing | Intervention Type: BEHAVIORAL; Name: GeneXpert HIV-1 Qual for point of care infant testing; Assigned to Arm(s): GeneXpert HIV-1 Qual for point of care infant testing | Intervention Type: BEHAVIORAL; Name: HIV DNA PCR testing (Standard of Care); Assigned to Arm(s): Alere q HIV-1/2 Detect for point of care infant testing, GeneXpert HIV-1 Qual for point of care infant testing
C: Arm Label: Primary Health care clinics; Type: N/A; Interventions: N/A | Arm Label: Pregnant and breast feeding women; Type: N/A; Interventions: N/A
D: Arm Label: In-vitro Diagnostics; Type: OTHER; Interventions: Other: In-vitro Diagnostics | Intervention Type: OTHER; Name: In-vitro Diagnostics; Assigned to Arm(s): In-vitro Diagnostics

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Take Active Breaks From Sitting (TABS): Reducing Sedentary Time in Older Adults
Brief Summary: The investigators are doing a study to learn how to support patients aged 60+ in taking more breaks from sitting and reducing total sitting time. The goal of the study is to find out if a sitting time reduction intervention reduces sitting time compared with a control group.


Options:
A: Arm Label: High Volume; Type: ACTIVE_COMPARATOR; Interventions: Other: High Volume | Arm Label: Moderate Volume; Type: ACTIVE_COMPARATOR; Interventions: Other: Moderate Volume | Intervention Type: OTHER; Name: Moderate Volume; Assigned to Arm(s): Moderate Volume | Intervention Type: OTHER; Name: High Volume; Assigned to Arm(s): High Volume
B: Arm Label: Short breaks; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short breaks | Arm Label: Long breaks; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Long breaks | Intervention Type: BEHAVIORAL; Name: Short breaks; Assigned to Arm(s): Short breaks | Intervention Type: BEHAVIORAL; Name: Long breaks; Assigned to Arm(s): Long breaks
C: Arm Label: High intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Low intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): High intensity intervention group, Low intensity intervention group
D: Arm Label: I-STAND; Type: EXPERIMENTAL; Interventions: Behavioral: I-STAND | Arm Label: Healthy Living; Type: ACTIVE_COMPARATOR; Interventions: Other: Healthy Living | Intervention Type: BEHAVIORAL; Name: I-STAND; Assigned to Arm(s): I-STAND | Intervention Type: OTHER; Name: Healthy Living; Assigned to Arm(s): Healthy Living

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Take Active Breaks From Sitting (TABS): Reducing Sedentary Time in Older Adults
Brief Summary: The investigators are doing a study to learn how to support patients aged 60+ in taking more breaks from sitting and reducing total sitting time. The goal of the study is to find out if a sitting time reduction intervention reduces sitting time compared with a control group.


Options:
A: Arm Label: I-STAND; Type: EXPERIMENTAL; Interventions: Behavioral: I-STAND | Arm Label: Healthy Living; Type: ACTIVE_COMPARATOR; Interventions: Other: Healthy Living | Intervention Type: BEHAVIORAL; Name: I-STAND; Assigned to Arm(s): I-STAND | Intervention Type: OTHER; Name: Healthy Living; Assigned to Arm(s): Healthy Living
B: Arm Label: Exercise programme only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SMS reminder; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise programme plus SMS reminders | Intervention Type: BEHAVIORAL; Name: Exercise programme plus SMS reminders; Assigned to Arm(s): SMS reminder
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: MyPlan 2.0 | Arm Label: Waiting-list control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MyPlan 2.0; Assigned to Arm(s): Intervention group
D: Arm Label: Sedentary behaviour reduction (behaviour change techniques); Type: EXPERIMENTAL; Interventions: Behavioral: Sedentary behaviour reduction using motivational interviewing, education, individualised feedback, goal-setting, self-monitoring, environmental modification, and supportive phone calls | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sedentary behaviour reduction using motivational interviewing, education, individualised feedback, goal-setting, self-monitoring, environmental modification, and supportive phone calls; Assigned to Arm(s): Sedentary behaviour reduction (behaviour change techniques)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.


Options:
A: Arm Label: Semaglutide 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide 1.0 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide placebo 0.5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Semaglutide placebo 1.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 0.5 mg | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 1.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Semaglutide placebo 0.5 mg, Semaglutide placebo 1.0 mg
B: Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68); Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68); Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Liraglutide Placebo, no Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Liraglutide 3.0mg, Pre-diabetes; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide Placebo, Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), Liraglutide Placebo, no Pre-diabetes | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg, Pre-diabetes | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide Placebo, Pre-diabetes
C: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo of vildagliptin | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: placebo of vildagliptin; Assigned to Arm(s): Placebo
D: Arm Label: Oral semaglutide; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Oral semaglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D